| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-3053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2809
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2833
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-725
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-15
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-21 |
| filingDate |
2010-07-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2012-12-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2012531904-A |
| titleOfInvention |
T cell receptor |
| abstract |
a T cell receptor (TCR) having the property of binding to the gp100 YLEPGPVTA peptide HLA-A2 complex and comprising a TCR alpha variable domain and / or a TCR beta variable domain, (i) the TCR has its alpha chain variable domain amino acids 1 to 109 of SEQ ID NO: 2 and / or the beta chain variable of SEQ ID NO: 3 compared to a TCR having the extracellular alpha and beta chain sequences of SEQ ID NOs: 2 and 3 Mutated in domain amino acids 1-112, (ii) the alpha variable domain has at least 90% sequence identity with amino acid sequence 1-109 of SEQ ID NO: 2 and / or the beta variable domain is at least with amino acid sequence 1-112 of SEQ ID NO: 3 90% sequence identity and (iii) the TCR has a binding affinity and / or binding half-life for the YLEPGPVTA-HLA-A2 complex at least twice that of the reference TCR, and the reference TCR is an extracellular alpha chain sequence of SEQ ID NO: 45 And an extracellular beta chain sequence of SEQ ID NO: 46. The use of such TCRs in adoptive therapy, and fusions of such TCRs with therapeutic agents are also described. [Selection figure] None |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2020529191-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2018512867-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2018533972-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-7174626-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-7125264-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2020501508-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2019517499-A |
| priorityDate |
2009-07-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |